Market News

Onconova Therapeutics, Inc. (ONTX) Analysts See $-0.71 EPS; Aramark Holdings (ARMK) Sentiment Is 0.84

Analysts expect Onconova Therapeutics, Inc. (NASDAQ:ONTX) to report $-0.71 EPS on March, 26.They anticipate $0.17 EPS change or 31.48% from last quarter’s $-0.54 EPS. After having $-0.71 EPS previously, Onconova Therapeutics, Inc.’s analysts see 0.00% EPS growth. The stock decreased 0.82% or $0.01 during the last trading session, reaching $1.21. About 583,266 shares traded or 82.88% up from the average. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has declined 60.57% since February 21, 2017 and is downtrending. It has underperformed by 77.27% the S&P500.

Aramark provides food, facilities, and uniform services to education, healthcare, business and industry, sports, leisure, and corrections clients in North America and internationally. The company has market cap of $10.35 billion. It offers managed services include dining, catering, food service management, convenience-oriented retail operations, grounds and facilities maintenance, custodial, energy and construction management, and capital project management. It has a 19.56 P/E ratio. The firm also provides non-clinical support services, such as patient food and nutrition, and retail food services; and facilities services comprising clinical equipment maintenance, environmental, laundry and linen distribution, plant operations, strategic/technical, energy and supply chain management, purchasing, and central transportation.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $23.50 million. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Onconova Therapeutics had 11 analyst reports since September 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, December 19 by H.C. Wainwright. H.C. Wainwright maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) on Thursday, January 18 with “Buy” rating. The firm earned “Buy” rating on Thursday, January 4 by H.C. Wainwright. The company was maintained on Tuesday, August 15 by Maxim Group. The firm has “” rating given on Thursday, September 3 by H.C. Wainwright. The firm has “Hold” rating given on Wednesday, January 31 by Maxim Group. On Wednesday, January 17 the stock rating was downgraded by Maxim Group to “Hold”. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) has “Buy” rating given on Thursday, November 9 by H.C. Wainwright. Maxim Group maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) on Tuesday, June 6 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 12 report.

Analysts await Aramark (NYSE:ARMK) to report earnings on May, 8. They expect $0.42 EPS, up 5.00% or $0.02 from last year’s $0.4 per share. ARMK’s profit will be $103.24M for 25.06 P/E if the $0.42 EPS becomes a reality. After $0.54 actual EPS reported by Aramark for the previous quarter, Wall Street now forecasts -22.22% negative EPS growth.

The stock increased 1.64% or $0.68 during the last trading session, reaching $42.1. About 338,888 shares traded. Aramark (ARMK) has risen 13.66% since February 21, 2017 and is uptrending. It has underperformed by 3.04% the S&P500.

Lionstone Capital Management Llc holds 9.5% of its portfolio in Aramark for 496,300 shares. Kensico Capital Management Corp owns 8.52 million shares or 5.25% of their US portfolio. Moreover, Steinberg Asset Management Llc has 2.73% invested in the company for 190,580 shares. The New York-based Global Thematic Partners Llc has invested 2.44% in the stock. Three Peaks Capital Management Llc, a Colorado-based fund reported 400,971 shares.

Ratings analysis reveals 60% of ARAMARK Holdings’s analysts are positive. Out of 5 Wall Street analysts rating ARAMARK Holdings, 3 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $36.0 while the high is $44.0. The stock’s average target of $39.20 is -6.89% below today’s ($42.1) share price. ARMK was included in 6 notes of analysts from August 13, 2015. The company was initiated on Friday, August 26 by Macquarie Research. RBC Capital Markets maintained Aramark (NYSE:ARMK) rating on Thursday, August 13. RBC Capital Markets has “Top Pick” rating and $36.0 target. The company was reinitiated on Friday, August 14 by Credit Suisse. RBC Capital Markets maintained the shares of ARMK in report on Wednesday, November 16 with “Top Pick” rating. Barclays Capital downgraded Aramark (NYSE:ARMK) rating on Tuesday, January 10. Barclays Capital has “Equal Weight” rating and $37.0 target. Robert W. Baird upgraded the stock to “Neutral” rating in Thursday, August 13 report.

Leave a Reply

Your email address will not be published. Required fields are marked *